ARTICLE | Clinical News
NBI 34041: Began Phase I Trial
January 2, 2001 8:00 AM UTC
Neurocrine Biosciences Inc. (NBIX), San Diego, Calif. Product: NBI 34041 Business: Neurological Therapeutic category: Receptor antagonist Target: CRF1 receptor Description: Corticotropin-releasing f...